PARD3 inactivation in lung squamous cell carcinomas impairs STAT3 and promotes malignant invasion

Cancer Research

Volumn 75, Issue 7, 2015, Pages 1287-1297

  Bonastre, Ester ^a   Verdura, Sara ^a   Zondervan, Ilse ^b   Facchinetti, Federica ^c   Lantuejoul, Sylvie ^d   Chiara, Maria Dolores ^e   Rodrigo, Juan Pablo ^e   Carretero, Julian ^f   Condom, Enric ^g   Vidal, Agustin ^g   Sidransky, David ^h   Villanueva, Alberto ⁱ   Roz, Luca ^c   Brambilla, Elisabeth ^d   Savola, Suvi ^b   Sanchez Cespedes, Montse ^a  

^a BELLVITGE BIOMEDICAL RESEARCH INSTITUTE IDIBELL   (Spain)

^b MRC Holland   (Netherlands)

^c NATIONAL CANCER INSTITUTE   (Italy)

^d INSTITUT ALBERT BONNIOT   (France)

^e HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^f UNIVERSITY OF VALENCIA   (Spain)

^g HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^h JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁱ CATALAN INSTITUTE OF ONCOLOGY   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIN; MUTANT PROTEIN; PARD3 PROTEIN; PROTEIN; PROTEIN KINASE C; PROTEIN P53; RAC1 PROTEIN; STAT3 PROTEIN; UNCLASSIFIED DRUG; CELL CYCLE PROTEIN; MEMBRANE PROTEIN; PARD3 PROTEIN, HUMAN; RAC1 PROTEIN, HUMAN; STAT3 PROTEIN, HUMAN; TRANSCRIPTOME;

ARTICLE; CELL ADHESION; CELL GROWTH; CELL JUNCTION; CELL POLARITY; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DOWNSTREAM PROCESSING; EXON; GENE EXPRESSION; GENE MUTATION; HUMAN; HUMAN CELL; IN VIVO STUDY; LUNG ADENOCARCINOMA; MAJOR CLINICAL STUDY; MICROARRAY ANALYSIS; PARD3 GENE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN PHOSPHORYLATION; SQUAMOUS CELL LUNG CARCINOMA; TIGHT JUNCTION; TUMOR INVASION; TUMOR SUPPRESSOR GENE; ANIMAL; CANCER TRANSPLANTATION; CELL MOTION; CELL PROLIFERATION; DNA SEQUENCE; GENETICS; LIVER TUMOR; LUNG TUMOR; METABOLISM; MUTATION; NUCLEOTIDE SEQUENCE; NUDE MOUSE; SECONDARY; SQUAMOUS CELL CARCINOMA; TUMOR CELL LINE;

ANIMALS; BASE SEQUENCE; CARCINOMA, SQUAMOUS CELL; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; HUMANS; LIVER NEOPLASMS; LUNG NEOPLASMS; MEMBRANE PROTEINS; MICE, NUDE; MUTATION; NEOPLASM INVASIVENESS; NEOPLASM TRANSPLANTATION; PROTEIN KINASE C; RAC1 GTP-BINDING PROTEIN; SEQUENCE ANALYSIS, DNA; STAT3 TRANSCRIPTION FACTOR; TRANSCRIPTOME;

EID: 84941640699     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-14-2444     Document Type: Article

References (46)

1. Ding L, Getz G, Wheeler DA, Mardis ER, McLellan MD, Cibullskis K, et al. Somatic mutations affect key pathways in lung adenocarcinoma. Nature 2008;455:1069-75.
2. Blanco R, Iwakawa R, Tang M, Kohno T, Angulo B, Pio R, et al. A gene-alteration profile of human lung cancer cell lines. Hum Mutat 2009;30:1199-206.
3. Sanchez-Cespedes M. Lung cancer biology: a genetic and genomic perspective. Clin Transl Oncol 2009;11:263-9.
4. Medina PP, Romero OA, Kohno T, Montuenga LM, Pio R, Yokota J, et al. Frequent BRG1/SMARCA4-inactivating mutations in human lung cancer cell lines. Hum Mutat 2008;29:617-22.
5. Weiss J, Sos ML, Seidel D, Peifer M, Zander T, Heuckmann JM, et al. Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. Sci Transl Med 2010;2:62ra93.
6. Bass AJ, Watanabe H, Mermel CH, Yu S, Perner S, Verhaak RG, et al. SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas. Nat Genet 2009;41:1238-42.
7. Hammerman PS, Sos ML, Ramos AH, Xu C, Dutt A, Zhou W, et al. Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer. Cancer Discov 2011;1:78-89.
8. Castillo SD, Angulo B, Suarez-Gauthier A, Melchor L, Medina PP, Sanchez-Verde L, et al. Gene amplification of the transcription factor DP1 and CTNND1 in human lung cancer. J Pathol 2010;222:89-98.
9. Cancer T, Atlas G. Comprehensive genomic characterization of squamous cell lung cancers. Nature 2012;489:519-25.
10. Hamada K, Kohno T, Kawanishi M, Ohwada S, Yokota J. Association of CDKN2A (p16)/CDKN2B (p15) alterations and homozygous chromosome arm 9p deletions in human lung carcinoma. Genes Chromosom Cancer 1998;22:232-40.
11. Sanchez-Cespedes M. A role for LKB1 gene in human cancer beyond the Peutz-Jeghers syndrome. Oncogene 2007;26:7825-32.
12. Rothenberg SM, Mohapatra G, Rivera MN, Winokur D, Greninger P, Nitta M, et al. A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers. Cancer Res 2010;70:2158-64.
13. Kemphues KJ, Priess JR, Morton DG, Cheng NS. Identification of genes required for cytoplasmic localization in early C. elegans embryos. Cell 1988;52:311-20.
14. Goldstein B, Macara IG. The PAR proteins: fundamental players in animal cell polarization. Dev Cell 2007;13:609-22.
15. Laprise P, Tepass U. Novel insights into epithelial polarity proteins in Drosophila. Trends Cell Biol 2011;7:401-8.
16. Martin-Belmonte F, Perez-Moreno M. Epithelial cell polarity, stem cells and cancer. Nat Rev Cancer 2012;12:23-38.
17. Iden S, van Riel WE, Schäfer R, Song J-Y, Hirose T, Ohno S, et al. Tumor type-dependent function of the par3 polarity protein in skin tumorigenesis. Cancer Cell 2012;22:389-403.
18. McCaffrey LM, Montalbano J, Mihai C, Macara IG. Loss of the Par3 polarity protein promotes breast tumorigenesis and metastasis. Cancer Cell 2012;22:601-14.
19. Leong PP, Rezai B, Koch WM, Reed A, Eisele D, Lee D, et al. Distinguishing second primary tumors from lung metastases in patients with head and neck squamous cell carcinoma. J Natl Cancer Inst 1998;90:972-7.
20. Xi T, Jones IM, Mohrenweiser HW. Many amino acid substitution variants identified in DNA repair genes during human population screenings are predicted to impact protein function. Genomics 2004;83:970-9.
21. Knudson AG. Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci U S A 1971;68:820-3.
22. Aranda V, Nolan ME, Muthuswamy SK. Par complex in cancer: a regulator of normal cell polarity joins the dark side. Oncogene 2008;27:6878-87.
23. Georgiou M, Baum B. Polarity proteins and Rho GTPases cooperate to spatially organise epithelial actin-based protrusions. J Cell Sci 2010;123:1089-98.
24. Pegtel DM, Ellenbroek SIJ, Mertens AEE, van der Kammen RA, de Rooij J, Collard JG. The Par-Tiam1 complex controls persistent migration by stabilizing microtubule-dependent front-rear polarity. Curr Biol 2007;17:1623-34.
25. Chen X, Macara IG. Par-3 controls tight junction assembly through the Rac exchange factor Tiam1. Nat Cell Biol 2005;7:262-9.
26. Rock KL, Gramm C, Rothstein L, Clark K, Stein R, Dick L, et al. Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules. Cell 1994;78:761-71.
27. Dabir S, Kluge A, McColl K. PIAS3 activates the intrinsic apoptotic pathway in non-small cell lung cancer cells independent of p53 status. Int J Cancer 2014;134:1045-54.
28. Raptis L, Arulanandam R, Geletu M, Turkson J. The R(h)oads to Stat3: Stat3 activation by the Rho GTPases. Exp Cell Res 2011;317:1787-95.
29. Steinman RA, Wentzel A, Lu Y, Stehle C, Grandis JR. Activation of Stat3 by cell confluence reveals negative regulation of Stat3 by cdk2. Oncogene 2003;22:3608-15.
30. Vultur A, Cao J, Arulanandam R, Turkson J, Jove R, Greer P, et al. Cell-to-cell adhesion modulates Stat3 activity in normal and breast carcinoma cells. Oncogene 2004;23:2600-16.
31. Vareille M, Kieninger E, Edwards MR, Regamey N. The airway epithelium: soldier in the Fight against respiratory viruses. Clin Microbiol Rev 2011;24:210-29.
32. Schumann M, Günzel D, Buergel N, Richter JF, Troeger H, May C, et al. Cell polarity-determining proteins Par-3 and PP-1 are involved in epithelial tight junction defects in coeliac disease. Gut 2012;61:220-8.
33. Mizuno K, Suzuki A, Hirose T, Kitamura K, Kutsuzawa K, Futaki M, et al. Self-association of PAR-3-mediated by the conserved N-terminal domain contributes to the development of epithelial tight junctions. J Biol Chem 2003;278:31240-50.
34. Sanchez-Cespedes M, Parrella P, Esteller M, Nomoto S, Trink B, Engles JM, et al. Inactivation of LKB1/STK11 is a common event in adenocarcinomas of the lung. Cancer Res 2002;62:3659-62.
35. Vaahtomeri K, Mäkelä TP. Molecular mechanisms of tumor suppression by LKB1. FEBS Lett 2011;585:944-51.
36. Benton R, Johnston DS. A conserved oligomerization domain in drosophila Bazooka/PAR-3 is important for apical localization and epithelial polarity. Curr Biol 2003;13:1330-4.
37. Lin D, Edwards AS, Fawcett JP, Mbamalu G, Scott JD, Pawson T. A mammalian PAR-3-PAR-6 complex implicated in Cdc42/Rac1 and aPKC signalling and cell polarity. Nat Cell Biol 2000;2:540-7.
38. Nakayama M, Goto TM, Sugimoto M, Nishimura T, Shinagawa T, Ohno S, et al. Rho-kinase phosphorylates PAR-3 and disrupts PAR complex formation. Dev Cell 2008;14:205-15.
39. Ishiuchi T, Takeichi M. Willin and Par3 cooperatively regulate epithelial apical constriction through aPKC-mediated ROCK phosphorylation. Nat Cell Biol 2011;13:860-6.
40. Hidalgo-Carcedo C, Hooper S, Chaudhry SI, Williamson P, Harrington K, Leitinger B, et al. Collective cell migration requires suppression of actomyosin at cell-cell contacts mediated by DDR1 and the cell polarity regulators Par3 and Par6. Nat Cell Biol 2011;13:49-58.
41. Wang C, Su H, Hsu Y, Shen M, Tang M. A discoidin domain receptor 1/SHP-2 signaling complex inhibits alpha2beta1-integrin-mediated signal transducers and activators of transcription 1/3 activation and cell migration. Mol Biol Cell 2006;17:2839-52.
42. Simon AR, Vikis HG, Stewart S, Fanburg BL, Cochran BH, Guan KL. Regulation of STAT3 by direct binding to the Rac1 GTPase. Science 2000;290:144-7.
43. Koskela HLM, Eldfors S, Ellonen P, van Adrichem AJ, Kuusanmäki H, Andersson EI, et al. Somatic STAT3 mutations in large granular lymphocytic leukemia. N Engl J Med 2012;366:1905-13.
44. Couto JP, Daly L, Almeida A, Knauf JA, Fagin JA, Sobrinho-Simões M, et al. STAT3 negatively regulates thyroid tumorigenesis. Proc Natl Acad Sci U S A 2012;109:E2361-70.
45. Kuo TH, Kubota T, Watanabe M, Furukawa T, Kase S, Tanino H, et al. Site-specific chemosensitivity of human small-cell lung carcinoma growing orthotopically compared to subcutaneously in SCID mice: the importance of orthotopic models to obtain relevant drug evaluation data. Anticancer Res 1993;13:627-30.
46. Ambrogio C, Carmona FJ, Vidal A, Falcone M, Nieto P, Romero OA, et al. Modeling lung cancer evolution and therapeutic response by orthotopic mouse allografts. Cancer Res 2014;74:5978-88.